PRRT

PRRT or Peptide Receptor Radionuclide Therapy is a molecular therapy used in the treatment of neuroendocrine tumors (NETs). This therapy involves the use of radiolabeled somatostatin analogues, which bind to the somatostatin receptors on the surface of the tumor cells, allowing for targeted radiation therapy.

Mechanism of Action

PRRT works by using a small peptide (somatostatin analogue) that is coupled to a radionuclide. The somatostatin analogue binds to the somatostatin receptors on the surface of the tumor cells. The radionuclide emits radiation, which damages the tumor cells and leads to their death.

Indications

PRRT is used in the treatment of neuroendocrine tumors, particularly those that express somatostatin receptors. These include gastroenteropancreatic neuroendocrine tumors (GEP-NETs), lung neuroendocrine tumors, and paraganglioma.

Side Effects

The most common side effects of PRRT include nausea, vomiting, and abdominal pain. Other side effects can include bone marrow suppression, kidney damage, and liver damage.

Future Directions

Research is ongoing to improve the efficacy and safety of PRRT. This includes the development of new radiolabeled somatostatin analogues, as well as combination therapies with other treatments.

See Also

• Neuroendocrine tumor
• Somatostatin
• Radiation therapy

PRRT Resources
Latest articles Most recent articles Ongoing trials	Wikipedia